Cogent Biosciences, Inc. COGT Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cogent Biosciences, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cogent Biosciences, Inc.'s change in accrued liabilities?
- Cogent Biosciences, Inc. (COGT) reported change in accrued liabilities of -$10.2M in Q1 2026.
- How has Cogent Biosciences, Inc.'s change in accrued liabilities changed year-over-year?
- Cogent Biosciences, Inc.'s change in accrued liabilities decreased by 17.8% year-over-year, from -$8.66M to -$10.2M.
- What is the long-term trend for Cogent Biosciences, Inc.'s change in accrued liabilities?
- Over 4 years (2021 to 2025), Cogent Biosciences, Inc.'s change in accrued liabilities has grown at a 32.8% compound annual growth rate (CAGR), from $3.43M to $10.69M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.